$ARGX News
Last published 2d ago
- 2d agoARGXargenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology CapabilitiesGlobeNewswirePairs Unnatural Products’ (UNP) peptide expertise with argenx's antibody engineering, expanding the ways to target novel biologyExtends argenx’s...
- 2d agoARGXUnnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation MedicinesGlobeNewswireArgenx to acquire UNP for $550 million upfront plus contingent value rights tied to development and regulatory milestones, for total potential value of up to approximately $1.15 billion Acquisition builds on the
- 2d agoARGXargenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology CapabilitiesGlobeNewswirePairs Unnatural Products’ (UNP) peptide expertise with argenx's antibody engineering, expanding the ways to target novel biologyExtends argenx’s immunology innovation to more patients, with the potential for oral
- 2d agoARGXUnnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation MedicinesGlobeNewswireArgenx to acquire UNP for $550 million upfront plus contingent value rights tied to development and regulatory milestones, for total potential value of up...
- 4d agoARGXargenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune MyositisGlobeNewswireALKIVIA met its primary and key secondary endpoints in the combined IMNM and DM populationFirst Phase 3 study to demonstrate statistically significant and clinically meaningful benefit in IMNM, an autoimmune myositis
- 4d agoARGXargenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune MyositisGlobeNewswireALKIVIA met its primary and key secondary endpoints in the combined IMNM and DM populationFirst Phase 3 study to demonstrate statistically significant...
- 1w agoARGXargenx to Present at Upcoming Investor ConferencesGlobeNewswireNovember 3, 2026 Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), the immunology innovation company, today announced that members of the management team will participate in the following investor
- 2w agoARGXargenx Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireContinued strong VYVGART performance drives $1.7 billion in global product net sales, representing 54% year-over-year growth and 13% quarter-over-quarter growth sBLA for VYVGART Hytrulo in IMNM on track for
- 3w agoARGXargenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026GlobeNewswireResults from the global Phase 3 ALKIVIA study, the first registrational study investigating an FcRn blocker in autoimmune myositis, show efgartigimod provides clinically meaningful improvements in IMNM and DMPatient
- 3w agoARGXargenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026GlobeNewswireOctober 15, 2026Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology innovation company, today announced that it will host a conference call and audio webcast on Thursday, October 22,
- 1mo agoARGXargenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's DiseaseGlobeNewswireOctober 8, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology innovation company, today announced that it will discontinue the Phase 3 UNITY study of
- 1mo agoARGXargenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac DiseaseGlobeNewswireStudy met primary endpoint of change from baseline in the ratio of Vh:Cd (p=0.0176)First Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage in people living with celiac diseaseargenx
- 1mo agoARGXargenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive DirectorsGlobeNewswireSeptember 17, 2026 – 22:01PM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology innovation company, today announced the results of the Extraordinary General Meeting of
- 2mo agoARGXargenx to Present at Upcoming Investor ConferencesGlobeNewswireSeptember 1, 2026Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology innovation company, today announced that members of the management team will participate in the following
- 2mo agoARGXFBRXargenx Completes Acquisition of Forte Biosciences, Inc.GlobeNewswireAcquisition adds first-in-class anti-CD122 Antibody, FB102, to argenx’s immunology pipeline August 27, 2026 – 8:50 AM ET Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology
- 2mo agoARGXARGENX AUGUST BUSINESS UPDATE - ARGENX SEEarnings Call TranscriptsGood morning. My name is Layla, and I will be your conference operator today. I would like to welcome everyone to the call. At this time, all lines have been placed on mute to prevent any background noise. After the spea
- 2mo agoZLABARGXZai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune MyositisBusiness WireStudy met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011) Patient improvements observed early and sustained throughout study;
- 2mo agoARGXargenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune MyositisGlobeNewswireStudy met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011)Patient improvements observed early and sustained throughout study;
- 3mo agoARGXFBRXargenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.GlobeNewswireAugust 6, 2026 – 7:45 AM ET Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology innovation company today announced that Avena Merger Sub Inc. ("Purchaser"), a wholly-owned
- 3mo agoARGXargenx announces Extraordinary General Meeting of Shareholders on September 17, 2026GlobeNewswireAugust 3, 2026 – 22:01 PM CEST Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology innovation company committed to improving the lives of people suffering from severe autoimmune
- 3mo agoFBRXARGXargenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology PipelineBusiness WireTransaction builds on argenx’s prior strategic investment in Forte Biosciences and reflects a disciplined approach to accessing novel biology that can fuel long-term growth FB102 Phase 1b studies in vitiligo and
- 3mo agoARGXFBRXargenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology PipelineGlobeNewswireTransaction builds on argenx’s prior strategic investment in Forte Biosciences and reflects a disciplined approach to accessing novel biology that can fuel long-term growthFB102 Phase 1b studies in vitiligo and celiac
- 3mo agoARGXargenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business UpdateGlobeNewswireStrong second quarter performance with $1.5 billion in global product net sales, representing 60% year-over-year growth and 17% quarter-over-quarter growth Successfully launched VYVGART and VYVGART Hytrulo in
- 3mo agoARGXargenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026GlobeNewswireJuly 16, 2026Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it
- 4mo agoARGXargenx to Host Autoimmune Myositis R&D WebinarGlobeNewswireJune 23, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will host
- 5mo agoARGXWilliam Blair 46th Annual Growth Stock Conference - ARGENX SEEarnings Call TranscriptsAll right, I think we'll get started. Welcome back to the 46th William Blair Annual Growth Stock Conference. My name is Myles Minter. I'm a Senior Biotech Analyst here at the firm. I'm joined here with Matt Phibbs, who's
- 5mo agoARGXargenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026GlobeNewswireALKIVIA+ data in myositis indicate efgartigimod provides sustained, clinically meaningful improvements and consistent safety RHO+ data in Sjogren's disease indicate maintenance of response following switch to biweekly
- 5mo agoARGXargenx to Host Myositis R&D Webinar on June 23, 2026GlobeNewswireMay 28, 2026Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will
- 5mo agoARGXargenx to Present at Upcoming Investor ConferencesGlobeNewswireMay 27, 2026Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that
- 5mo agoARGXCGEMHYFTIDXX+2The Biology Came First.Business WireOver 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological
- 6mo agoARGXargenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMGGlobeNewswireVYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients living with gMG – anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple
- 6mo agoARGXargenx Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire$1.3 billion in first quarter global product net sales, representing 63% year-over-year growth Anti-AChR antibody negative ("seronegative") gMG PDUFA is May 10, 2026 Management to host conference call today at 2:30
- 6mo agoARGXargenx to Present at BofA Securities 2026 Health Care ConferenceGlobeNewswireMay 6, 2026Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karen
- 6mo agoARGXargenx Announces Results of Annual General Meeting and Board of Directors' Appointment of Karen Massey as Chief Executive OfficerGlobeNewswireLeadership transition marks next evolution of growth May 6, 2026 Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology innovator committed to improving the lives of people
- 6mo agoARGXargenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026GlobeNewswireApril 30, 2026Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it
- 6mo agoARGXargenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDPGlobeNewswireADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease symptoms in this underserved patient populationADAPT SERON, OCULUS, and Jr study
- 8mo agoARGXargenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of PipelineGlobeNewswirePositive results from Phase 3 ADAPT OCULUS study show VYVGART's potential as the first targeted treatment for patients living with ocular MG Additional data from ADAPT SERON – the largest study of patients with gMG who
- 8mo agoARGXargenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business UpdateGlobeNewswire$1.3 billion in fourth quarter and $4.2 billion in full year global product net sales, representing 90% year‑over‑year growth Delivered $1.1 billion in operating income in 2025, marking first year of operating
- 8mo agoARGXargenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia GravisGlobeNewswireStudy met primary endpoint (p-value = 0.012)First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG Results support planned Supplemental Biologics License Application
- 8mo agoARGXargenx to Present at TD Cowen 46th Annual Healthcare ConferenceGlobeNewswireFebruary 23, 2026Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that
- 8mo agoARGXargenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026GlobeNewswireFebruary 19, 2026Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that
- 10mo agoARGXargenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMGGlobeNewswireJanuary 13, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,
- 10mo agoARGXargenx Highlights 2026 Strategic PrioritiesGlobeNewswireReported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales VYVGART impact continues with approximately 19,000 patients
- 10mo agoARGXargenx to Present at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireJanuary 6, 2026Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim
- 10mo agoARGXargenx Announces Leadership Transition Marking Next Evolution of GrowthGlobeNewswireTim Van Hauwermeiren to transition from CEO to Non-Executive Director and Chairman of Board of Directors and Karen Massey to transition from COO to CEO and Executive Director January 5, 2026 7:00 a.m. CET Amsterdam,
- 11mo agoARGXargenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye DiseaseGlobeNewswire15 December, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,
- 11mo agoARGXargenx Announces Results of Extraordinary General Meeting of ShareholdersGlobeNewswireNovember 18, 2025 – 10:01 PM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,
- 1y agoARGXargenx Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire$1.13 billion in third quarter global product net sales On track to submit seronegative gMG sBLA by year-end and report ADAPT-OCULUS results in 1H26 – supporting pursuit of broadest MG label of any biologic Five
- 1y agoARGXargenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis PatientsGlobeNewswireVYVGART demonstrated clinically meaningful benefit across all AChR-Ab seronegative gMG subtypes in ADAPT SERON, supporting broad role of pathogenic IgGs in disease activityFinal ADAPT SC+ results show ~60% of VYVGART
- 1y agoARGXargenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025GlobeNewswireOctober 23, 2025Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it